Previous 10 | Next 10 |
Arena Pharmaceuticals (NASDAQ:ARNA) has achieved target enrollment in Study A of Phase 2/3 CULTIVATE trial evaluating the safety and efficacy of etrasimod, in participants with moderate to severe Crohn's disease (CD). CULTIVATE Study A reached target enrollment of 70 study participants to ass...
- Evaluating 2 mg and 3 mg etrasimod in study participants with moderate to severe Crohn's Disease (CD) - Topline data from CULTIVATE Study A on track for Q2 2022 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has achieved target enrollment in Stu...
Image source: The Motley Fool. Arena Pharmaceuticals, inc (NASDAQ: ARNA) Q3 2021 Earnings Call Nov 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Arena Pharmaceuticals, inc (ARNA) Q3 2021 Earnings Call Transcrip...
Arena Pharmaceuticals, Inc. (ARNA) Q3 2021 Earnings Conference Call November 4, 2021 16:30 ET Company Participants Patrick Malloy - Vice President of Investor Relations & Corporate Communications Amit Munshi - President, Chief Executive Officer & Director Laurie Stelzer - Executive Vi...
Arena Pharmaceuticals said that top-line data for two phase 3 trials of its ulcerative colitis candidate etrasimod is on track for Q1 2022. The candidate is also in phase 2 for alopecia areata. Top-line data for that trial is expected in 2H 2022. In its Q3 2021 earnings, Arena saw i...
Arena Pharmaceuticals (NASDAQ:ARNA): Q3 GAAP EPS of -$3.21 misses by $0.74. Press Release Cash, cash equivalents and marketable securities were $0.8 billion at September 30, 2021 as compared to $1.1 billion at December 31, 2020. In addition to normal operating cash burn for the quarter, we ma...
– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout – First participant randomized in the Phase 2 trial for temanogrel in Raynaud’s phenomenon secondary to systemic sclerosis – Strong liquidity position to s...
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and l...
After the recent FDA black box warning of JAKi, Arena Pharmaceuticals' share price has rallied recovering some of its 2021 losses. In this article, Etrasimod's ulcerative colitis phase 2 data will be analyzed and explain what our views for the S1P-R class moving forward. Arena Pha...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2020, the race for the Covid-19 vaccine distorted investment inflows in the biotechnology sector. Back then, emerging biotech stocks tripled or more on hopes that they would come out with a vaccine. Buying interest in ...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...